<H1>Chapter DOI: 10.1007/978-1-60327-829-4_12<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>100</td></tr><tr><td>Springer references</td><td>6</td></tr><tr><td>Non Springer references</td><td>94</td></tr><tr><td>BibStructured Count</td><td width="10%">99</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>72</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_12</td><td>BibArticle</td><td>Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin 2008;58(2):71&#8211;96.</td><td><a href=http://dx.doi.org/10.3322/CA.2007.0010>10.3322/CA.2007.0010</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2_12</td><td>BibArticle</td><td>Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25(12):1596&#8211;605.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.10.1949>10.1200/JCO.2006.10.1949</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_12</td><td>BibArticle</td><td>Lucas A, Petrylak DP. The case for early chemotherapy for the treatment of metastatic disease. J Urol 2006;176(6 Pt 2): S72&#8211;5.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2006.06.077>10.1016/j.juro.2006.06.077</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_12</td><td>BibArticle</td><td>Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17(8):2506&#8211;13.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR5_12</td><td>BibArticle</td><td>Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14(6):1756&#8211;64.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6_12</td><td>BibArticle</td><td>Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Cell Biol 1981;91(2 Pt 1):479&#8211;87.</td><td><a href=http://dx.doi.org/10.1083/jcb.91.2.479>10.1083/jcb.91.2.479</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7_12</td><td>BibArticle</td><td>Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277(5698):665&#8211;7.</td><td><a href=http://dx.doi.org/10.1038/277665a0>10.1038/277665a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_12</td><td>BibArticle</td><td>Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 1980;77(3):1561&#8211;5.</td><td><a href=http://dx.doi.org/10.1073/pnas.77.3.1561>10.1073/pnas.77.3.1561</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_12</td><td>BibArticle</td><td>Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res 1994;24(1):6&#8211;14.</td><td><a href=http://dx.doi.org/10.1007/BF02592403>10.1007/BF02592403</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_12</td><td>BibArticle</td><td>Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 1993;72(8):2457&#8211;60.</td><td><a href=http://dx.doi.org/10.1002/1097-0142(19931015)72:8&lt;2457::AID-CNCR2820720825&gt;3.0.CO;2-Z>10.1002/1097-0142(19931015)72:8&lt;2457::AID-CNCR2820720825&gt;3.0.CO;2-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_12</td><td>BibArticle</td><td>Tew KD, Glusker JP, Hartley-Asp B, Hudes G, Speicher LA. Preclinical and clinical perspectives on the use of estramustine as an antimitotic drug. Pharmcol Ther 1992;56(3):323&#8211;39.</td><td><a href=http://dx.doi.org/10.1016/0163-7258(92)90023-S>10.1016/0163-7258(92)90023-S</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_12</td><td>BibArticle</td><td>Speicher LA, Barone L, Tew KD. Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res 1992;52(16):4433&#8211;40.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR13_12</td><td>BibArticle</td><td>Haas N, Roth B, Garay C, et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001;58(1):59&#8211;64.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(01)01011-1>10.1016/S0090-4295(01)01011-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_12</td><td>BibArticle</td><td>Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 1992;147(3 Pt 2):931&#8211;4.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR15_12</td><td>BibArticle</td><td>Hudes GR, Greenberg R, Krigel RL, et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 1992;10(11):1754&#8211;61.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR16_12</td><td>BibArticle</td><td>Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 1995;22(3 Suppl 6):6&#8211;11.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17_12</td><td>BibArticle</td><td>Hudes GR, Nathan F, Khater C, et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997;15(9):3156&#8211;63.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_12</td><td>BibArticle</td><td>Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 1991;83(4):288&#8211;91.</td><td><a href=http://dx.doi.org/10.1093/jnci/83.4.288>10.1093/jnci/83.4.288</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_12</td><td>BibArticle</td><td>Vidensek N, Lim P, Campbell A, Carlson C. Taxol content in bark, wood, root, leaf, twig, and seedling from several Taxus species. J Nat Prod1990;53(6):1609&#8211;10.</td><td><a href=http://dx.doi.org/10.1021/np50072a039>10.1021/np50072a039</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_12</td><td>BibArticle</td><td>Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51(18):4845&#8211;52.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR21_12</td><td>BibArticle</td><td>Vogel M, Hilsenbeck SG, Depenbrock H, et al. Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer 1993;29A(14):2009&#8211;14.</td><td><a href=http://dx.doi.org/10.1016/0959-8049(93)90463-P>10.1016/0959-8049(93)90463-P</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_12</td><td>BibArticle</td><td>Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P, Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995;22(2 Suppl 4):3&#8211;16.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_12</td><td>BibArticle</td><td>Budman DR, Calabro A, Kreis W. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro. Anticancer Drugs 2002;13(10):1011&#8211;6.</td><td><a href=http://dx.doi.org/10.1097/00001813-200211000-00005>10.1097/00001813-200211000-00005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_12</td><td>BibArticle</td><td>Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79(2):196&#8211;202.</td><td><a href=http://dx.doi.org/10.1046/j.1464-410X.1997.06310.x>10.1046/j.1464-410X.1997.06310.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25_12</td><td>BibArticle</td><td>Picus J, Schultz M. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 1999;26(5 Suppl 17):14&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR26_12</td><td>BibArticle</td><td>Petrylak DP, Macarthur RB, O&#8217;Connor J, et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 1999;17(3):958&#8211;67.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR27_12</td><td>BibArticle</td><td>Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol 1999;10(1):33&#8211;8.</td><td><a href=http://dx.doi.org/10.1023/A:1008354600497>10.1023/A:1008354600497</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28_12</td><td>BibArticle</td><td>Petrylak DP, Macarthur R, O&#8217;Connor J, et al. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer. Semin Oncol 1999;26(5 Suppl 17):28&#8211;33.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR29_12</td><td>BibArticle</td><td>Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. Semin Oncol 1999;26(5 Suppl 17):39&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR30_12</td><td>BibArticle</td><td>Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351(15):1502&#8211;12.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa040720>10.1056/NEJMoa040720</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_12</td><td>BibArticle</td><td>Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008;26(2):242&#8211;5.</td><td><a href=http://dx.doi.org/10.1200/JCO.2007.12.4008>10.1200/JCO.2007.12.4008</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_12</td><td>BibArticle</td><td>Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19(10):1749&#8211;53.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdn288>10.1093/annonc/mdn288</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_12</td><td>BibArticle</td><td>Saad F, Ruether D, Ernst S, et al. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int 2008;102(5):551&#8211;5.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2008.07733.x>10.1111/j.1464-410X.2008.07733.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34_12</td><td>BibArticle</td><td>Slaviero KA, Clarke SJ, McLachlan AJ, Blair EY, Rivory LP. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004;57(1):44&#8211;53.</td><td><a href=http://dx.doi.org/10.1046/j.1365-2125.2003.01956.x>10.1046/j.1365-2125.2003.01956.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35_12</td><td>BibArticle</td><td>Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004;9(5):538&#8211;45.</td><td><a href=http://dx.doi.org/10.1634/theoncologist.9-5-538>10.1634/theoncologist.9-5-538</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36_12</td><td>BibArticle</td><td>Petrylak DP. Chemotherapy for androgen-independent prostate cancer. World J Urol 2005;23(1):10&#8211;3.</td><td><a href=http://dx.doi.org/10.1007/s00345-004-0482-0>10.1007/s00345-004-0482-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_12</td><td>BibArticle</td><td>Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New Engl J Med 2004;351(15):1513&#8211;20.</td><td><a href=http://dx.doi.org/10.1056/NEJMoa041318>10.1056/NEJMoa041318</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR38_12</td><td>BibArticle</td><td>Berry DL, Moinpour CM, Jiang CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol 2006;24(18):2828&#8211;35.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.04.8207>10.1200/JCO.2005.04.8207</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_12</td><td>BibArticle</td><td>Petrylak DP. New paradigms for advanced prostate cancer. Rev Urol 2007;9(Suppl 2):S3&#8211;12.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR40_12</td><td>BibArticle</td><td>Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74(4):609&#8211;19.</td><td><a href=http://dx.doi.org/10.1016/0092-8674(93)90509-O>10.1016/0092-8674(93)90509-O</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41_12</td><td>BibArticle</td><td>Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6(1):48&#8211;54.</td><td><a href=http://dx.doi.org/10.1038/sj.cdd.4400453>10.1038/sj.cdd.4400453</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_12</td><td>BibArticle</td><td>Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 2005;11(13):4905&#8211;11.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-04-2140>10.1158/1078-0432.CCR-04-2140</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_12</td><td>BibArticle</td><td>Tang Y, Khan MA, Goloubeva O, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006;12(1):169&#8211;74.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-1388>10.1158/1078-0432.CCR-05-1388</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_12</td><td>BibArticle</td><td>Hussain A, Dawson N, Amin P, et al. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 2005;23(12):2789&#8211;96.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.07.152>10.1200/JCO.2005.07.152</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_12</td><td>BibArticle</td><td>Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002;168(6):2439&#8211;43.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)64163-8>10.1016/S0022-5347(05)64163-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_12</td><td>BibArticle</td><td>Hamberg P, Verhagen PC, de Wit R. When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 2008;44(9):1193&#8211;7.</td><td><a href=http://dx.doi.org/10.1016/j.ejca.2008.04.005>10.1016/j.ejca.2008.04.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_12</td><td>BibArticle</td><td>Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13(21):6396&#8211;403.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-1036>10.1158/1078-0432.CCR-07-1036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_12</td><td>BibArticle</td><td>Oudard S, Banu E, Scotte F, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007;18(11):1828&#8211;33.</td><td><a href=http://dx.doi.org/10.1093/annonc/mdm332>10.1093/annonc/mdm332</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49_12</td><td>BibArticle</td><td>Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971;285(21):1182&#8211;6.</td><td><a href=http://dx.doi.org/10.1056/NEJM197111182852108>10.1056/NEJM197111182852108</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_12</td><td>BibArticle</td><td>Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369&#8211;72.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51_12</td><td>BibArticle</td><td>Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 2005;23(6):1295&#8211;311.</td><td><a href=http://dx.doi.org/10.1200/JCO.2005.10.022>10.1200/JCO.2005.10.022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_12</td><td>BibArticle</td><td>Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089&#8211;94.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2008.01.082>10.1016/j.eururo.2008.01.082</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_12</td><td>BibArticle</td><td>Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid<Superscript>&#174;</Superscript> (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57(12):1849&#8211;59.</td><td><a href=http://dx.doi.org/10.1007/s00262-008-0512-7>10.1007/s00262-008-0512-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_12</td><td>BibArticle</td><td>Sanborn SL, Cooney MM, Dowlati A, et al. Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. Invest New Drugs 2008;26(4):355&#8211;62.</td><td><a href=http://dx.doi.org/10.1007/s10637-008-9137-0>10.1007/s10637-008-9137-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR55_12</td><td>BibArticle</td><td>Ning Y, Arlen P, Fulley J, et al. Phase II trial of thalidomide (T), bevacizumab (Bv), and docetaxel (DOC) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC). J Clin Oncol 2008;26:abstr 5000.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR56_12</td><td>BibArticle</td><td>Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008;270(2):229&#8211;33.</td><td><a href=http://dx.doi.org/10.1016/j.canlet.2008.05.007>10.1016/j.canlet.2008.05.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57_12</td><td>BibArticle</td><td>Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008;134(1):51&#8211;7.</td><td><a href=http://dx.doi.org/10.1007/s00432-007-0247-4>10.1007/s00432-007-0247-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58_12</td><td>BibArticle</td><td>George D, Liu G, Wilding G, et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone refractor prostate cancer (mHRPC) &#8211; preliminary results. J Clin Oncol 2008;26:abstr 5131.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR59_12</td><td>BibUnstructured</td><td>ClinicalTrials.gov. Accessed <span style='background:#66FF66'>2008</span>, at <span style='background:#FF3300'>http://www.clinicaltrials.gov</span></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR60_12</td><td>BibArticle</td><td>Wang YR, Wigington DP, Strugnell SA, Knutson JC. Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug. Anticancer Res 2005;25(6B):4333&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_12</td><td>BibArticle</td><td>Blutt SE, Polek TC, Stewart LV, Kattan MW, Weigel NL. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res 2000;60(4):779&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR62_12</td><td>BibArticle</td><td>Hershberger PA, Yu WD, Modzelewski RA, Rueger RM, Johnson CS, Trump DL. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 2001;7(4):1043&#8211;51.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR63_12</td><td>BibArticle</td><td>Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001;28(4 Suppl 15):49&#8211;55.</td><td><a href=http://dx.doi.org/10.1016/S0093-7754(01)90155-1>10.1016/S0093-7754(01)90155-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_12</td><td>BibArticle</td><td>Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 2007;25(6):669&#8211;74.</td><td><a href=http://dx.doi.org/10.1200/JCO.2006.06.8197>10.1200/JCO.2006.06.8197</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65_12</td><td>BibArticle</td><td>Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008;40(8):1443&#8211;51.</td><td><a href=http://dx.doi.org/10.1016/j.biocel.2008.01.022>10.1016/j.biocel.2008.01.022</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR66_12</td><td>BibArticle</td><td>Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006;12(20 Pt 2):6296s&#8211;300s.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-0929>10.1158/1078-0432.CCR-06-0929</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_12</td><td>BibArticle</td><td>Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5(3):419&#8211;27.</td><td><a href=http://dx.doi.org/10.1586/14737140.5.3.419>10.1586/14737140.5.3.419</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_12</td><td>BibArticle</td><td>Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4):679&#8211;89.</td><td><a href=http://dx.doi.org/10.1200/JCO.2003.04.176>10.1200/JCO.2003.04.176</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_12</td><td>BibArticle</td><td>Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007;67(8):3818&#8211;26.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-06-3879>10.1158/0008-5472.CAN-06-3879</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_12</td><td>BibArticle</td><td>Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994;263(5146):526-9.</td><td><a href=http://dx.doi.org/10.1126/science.8290962>10.1126/science.8290962</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_12</td><td>BibArticle</td><td>Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007;446(7136):690&#8211;4.</td><td><a href=http://dx.doi.org/10.1038/nature05656>10.1038/nature05656</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_12</td><td>BibArticle</td><td>Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther 2008;7(7):2160&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1535-7163.MCT-08-0046>10.1158/1535-7163.MCT-08-0046</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_12</td><td>BibArticle</td><td>Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 2007;13(4):1208&#8211;15.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-06-2046>10.1158/1078-0432.CCR-06-2046</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74_12</td><td>BibArticle</td><td>Cao W, Shiverick KT, Namiki K, et al. Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation. World J Urol 2008;26(5):509&#8211;16.</td><td><a href=http://dx.doi.org/10.1007/s00345-008-0289-5>10.1007/s00345-008-0289-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_12</td><td>BibArticle</td><td>Morris M, Beekman K, Kelly W, et al. Phase II study of bortezomib for castrate metastatic prostate cancer. Proc Am Soc Clin Oncol 2005;23:411S(abstract 4633).</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR76_12</td><td>BibArticle</td><td>Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004;22(11):2108&#8211;21.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.02.106>10.1200/JCO.2004.02.106</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77_12</td><td>BibArticle</td><td>Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122&#8211;32.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.08.083>10.1200/JCO.2004.08.083</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78_12</td><td>BibArticle</td><td>Kaufman H, Wang W, Manola J, et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: follow up clinical results from ECOG 7897. Proc Am Soc Clin Oncol 2005;24:4501a.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR79_12</td><td>BibArticle</td><td>Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12(4):1260&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-2059>10.1158/1078-0432.CCR-05-2059</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR80_12</td><td>BibArticle</td><td>Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14(11):3536&#8211;44.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4025>10.1158/1078-0432.CCR-07-4025</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81_12</td><td>BibArticle</td><td>Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172(3):910&#8211;4.</td><td><a href=http://dx.doi.org/10.1097/01.ju.0000134888.22332.bb>10.1097/01.ju.0000134888.22332.bb</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82_12</td><td>BibArticle</td><td>Pickles T, Morgan S, Morton G, Souhami L, Warde P, Lukka H. Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement. Can Urol Assoc J (Journal de l&#8217;Association des urologues du Canada) 2008;2(2):95&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR83_12</td><td>BibArticle</td><td>Sonpavde G, Chi KN, Powles T, et al. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer 2007;110(12):2628&#8211;39.</td><td><a href=http://dx.doi.org/10.1002/cncr.23085>10.1002/cncr.23085</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84_12</td><td>BibArticle</td><td>Carson CC III, Zincke H, Utz DC, Cupps RE, Farrow GM. Radical prostatectomy after radiotherapy for prostatic cancer. J Urol 1980;124(2):237&#8211;9.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR85_12</td><td>BibArticle</td><td>Garcia JA, Klein EA, Magi-Galluzzi C, Elson P, Triozzi P, Dreicer R. Clinical and biological effects of neoadjuvant sargramostim and thalidomide in patients with locally advanced prostate carcinoma. Clin Cancer Res 2008;14(10):3052&#8211;9.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-07-4731>10.1158/1078-0432.CCR-07-4731</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86_12</td><td>BibArticle</td><td>Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003;61(4):774&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/S0090-4295(02)02519-0>10.1016/S0090-4295(02)02519-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87_12</td><td>BibArticle</td><td>Dreicer R, Magi-Galluzzi C, Zhou M, et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004;63(6):1138&#8211;42.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2004.01.040>10.1016/j.urology.2004.01.040</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88_12</td><td>BibArticle</td><td>Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005;11(14):5233&#8211;40.</td><td><a href=http://dx.doi.org/10.1158/1078-0432.CCR-05-0299>10.1158/1078-0432.CCR-05-0299</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89_12</td><td>BibArticle</td><td>Garzotto M, Myrthue A, Higano CS, Beer TM. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 2006;24(3):254&#8211;9.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2005.11.034>10.1016/j.urolonc.2005.11.034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR90_12</td><td>BibArticle</td><td>Friedman J, Dunn RL, Wood D, et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008;179(3):911&#8211;5; discussion 5&#8211;6.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.10.064>10.1016/j.juro.2007.10.064</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91_12</td><td>BibArticle</td><td>Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008;180(2):565&#8211;70; discussion 70.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2008.04.012>10.1016/j.juro.2008.04.012</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92_12</td><td>BibArticle</td><td>Eastham JA, Kelly WK, Grossfeld GD, Small EJ. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003;62(Suppl 1):55&#8211;62.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2003.09.052>10.1016/j.urology.2003.09.052</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR93_12</td><td>BibArticle</td><td>Eisenberger M, Kattan M, Kibel A, Sternberg C, Epstein J. Impact of central pathology review (CPR) of radical prostatectomy (RP) specimens for patient selection in the surgical adjuvant trial in prostate cancer (PCa) TAX-3501. J Clin Oncol 2008;26:abstr 5128.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR94_12</td><td>BibArticle</td><td>Kibel AS, Rosenbaum E, Kattan MW, et al. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol 2007;177(5):1777&#8211;81.</td><td><a href=http://dx.doi.org/10.1016/j.juro.2007.01.028>10.1016/j.juro.2007.01.028</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95_12</td><td>BibArticle</td><td>Montgomery B, Lavori P, Garzotto M, et al. Veterans Affairs Cooperative Studies Program Study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer. Urology 2008;72(3):474&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/j.urology.2008.02.050>10.1016/j.urology.2008.02.050</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96_12</td><td>BibArticle</td><td>Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3(12 Pt 1):2431&#8211;8.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR97_12</td><td>BibArticle</td><td>Kumar P, Perrotti M, Weiss R, et al. Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol 2004;22(10):1909&#8211;15.</td><td><a href=http://dx.doi.org/10.1200/JCO.2004.02.001>10.1200/JCO.2004.02.001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98_12</td><td>BibArticle</td><td>Perrotti M, Doyle T, Kumar P, et al. Phase I/II trial of docetaxel and concurrent radiation therapy in localized high risk prostate cancer (AGUSG 03-10). Urol Oncol 2008;26(3):276&#8211;80.</td><td><a href=http://dx.doi.org/10.1016/j.urolonc.2007.04.003>10.1016/j.urolonc.2007.04.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99_12</td><td>BibBook</td><td>Ebrrahimi K, Ruckle H, Harper J, et al. Post prostatectomy multimodality adjuvant therapy for patients at high risk for prostate cancer relapse. In: American Urologic Association Annual Meeting, Orlando;2008.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(08)61643-2>10.1016/S0022-5347(08)61643-2</a></td><td><b>CrossRef-Meta</b></td>
<td>BookTitle, Year, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR100_12</td><td>BibArticle</td><td>Patel AR, Sandler HM, Pienta KJ. Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer. Clinical Genitourin Cancer 2005;4(3):212&#8211;4.</td><td><a href=http://dx.doi.org/10.3816/CGC.2005.n.035>10.3816/CGC.2005.n.035</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>